Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07681323
Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer
Sponsor: Geneplus-Beijing Co. Ltd.
View on ClinicalTrials.gov
Summary
This multicenter, prospective observational cohort study aims to investigate the impact of ctDNA level and key actionable gene mutation status on prognosis and treatment response in patients with advanced HR+/HER2- breast cancer.
Official title: Timing of ctDNA Testing in Advanced Breast Cancer: Impact on Prognosis and Treatment Strategies - A Prospective Observational Study (TIMING)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2026-06-30
Completion Date
2029-06-30
Last Updated
2026-07-02
Healthy Volunteers
No
Conditions
Locations (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China